How to appeal a Humana compounded glp-1 denial
42 CFR Part 422 Subpart M (Medicare Advantage) · 60-day window · 30-day decision
To appeal a Humana compounded glp-1 denial, file an internal appeal within 60 days of the date on the denial letter through Humana's member or provider portal, under 42 CFR Part 422 Subpart M (Medicare Advantage). Humana returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).
Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
What Humana's policy requires for compounded glp-1
Cited policy: Humana / Anthem Pharmacy Policy — Anti-Obesity Medications (transition compounded → branded)
Branded Wegovy / Zepbound under PA; tier-3 placement with high copay. Compounded categorically excluded.
How Humana denies compounded glp-1 — and how to counter it
Where Humana pushes back: 1) Compounded prior use does not establish PA; 2) Step therapy required.
Counter-arguments that hold up: Continuity of care: patient has demonstrated tolerance + response to GLP-1 mechanism via compounded; switching to branded is not a 'new start' for step-therapy purposes. STEP 4 (Wilding 2022) — abrupt discontinuation produces rapid weight regain. Manufacturer copay programs (NovoCare / LillyDirect) may cover gap. Cross-link to glp1 vertical's branded PA support.
What Humana typically denies for compounded glp-1
Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For compounded glp-1, expect:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
Treatments most often denied in this category
These are the compounded glp-1 treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Compounded sema injectable
- Compounded sema oral
- Compounded tirz injectable
- Sema + B12 combo
- Tirz + B12 combo
- Reimbursement past sema
How to submit the appeal to Humana
- Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
- File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Humana compounded glp-1 denial?
Humana allows 60 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Humana appeal?
Members can submit through the Humana member portal at https://www.humana.com. Providers should use the provider portal at https://www.humana.com/provider. Faxed and mailed appeals are accepted but take longer.
What denials does Humana most often issue for compounded glp-1?
For compounded glp-1, Humana most often denies on: 1) Compounded prior use does not establish PA; 2) Step therapy required. The strongest counters: Continuity of care: patient has demonstrated tolerance + response to GLP-1 mechanism via compounded; switching to branded is not a 'new start' for step-therapy purposes. STEP 4 (Wilding 2022) — abrupt discontinuation produces rapid weight regain. Manufacturer copay programs (NovoCare / LillyDirect) may cover gap. Cross-link to glp1 vertical's branded PA support.
What if Humana denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Compounded GLP-1 appeal
Upload your Humana denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to 42 CFR Part 422 Subpart M (Medicare Advantage).
Get started →Contact: hello@denialhelp.com